鸡胚尿囊膜（HET-CAM）眼刺激替代试验对产品及原料评价的比较

目的比较鸡胚尿囊膜试验（HET-CAM）作为一种眼刺激替代方法对产品或原料的评价。方法采用HET-CAM和兔眼Draize试验方法,对19种原料和23种化妆品及家用洗涤产品眼刺激性进行检测,对体内体外试验的结果进行统计比较。结果比较体内体外试验,原料和产品的kappa系数分别为0.826,0.531;灵敏度分别为100%,81.8%;特异度分别为85.7%,77.8%。结论 HET-CAM可作为Draize试验的替代试验,HET-CAM系统更适合对单纯化学品原料进行眼刺激试验。     

皮肤刺激实验替代模型的研究新进展

皮肤刺激性是日常使用化妆品最常见的不良反应之一。人类健康相关产品危险性评价常做皮肤刺激性实验,皮肤刺激性试验是化妆品原料及产品安全性评价的主要项目。传统皮肤刺激试验采用实验动物进行,2013年3月11日欧盟已经禁止销售基于动物实验研发的化妆品原料及产品.随着组织工程技术和现代生物技术的发展,多种替代动物试验的体外模型被开发和应用,新的的皮肤刺激物陆续被发现。欧盟多采纳重组人表皮实验方法作为新体外皮肤实验指南(包括模型Episkin和模型Epiderm),随着体外模型重建技术的不断改善,不仅拓展了皮肤模型的临床应用范围,也必然推动新的敏感而特异的皮肤标志物的发现和应用。     

GLP原则在体外毒理学评价实验室的应用

在动物福利运动的推动下,以减少、优化和替代动物试验为核心内容的体外试验系统已成为安全评价不可或缺的组成部分,在药品、化学品、化妆品毒理学评价中起到重要作用。体外试验系统不同于体内动物实验,体外毒理学实验室GLP原则的建立和运行应充分考虑体外试验系统的特殊性。目前我国专业的体外安全评价实验室的建设刚刚起步,还没有可供借鉴的成熟经验。本文从实验室组织、试验系统维护、人员职责、质量管理和运行几个方面,介绍了GLP原则在化妆品体外毒理学检验和评价实验室的应用。     

体外皮肤刺激模型的生物标志研究进展

皮肤刺激试验是人类健康相关产品危险性评价的常见项目,传统皮肤刺激试验采用实验动物进行,成本高周期长,给动物造成一定程度的痛苦。近年来,多种替代动物试验的体外模型被开发和应用。体外试验主要通过定量检测细胞活性和代谢变化的生物标志物预测体内的效应,应用最广泛的生物标志物是细胞活性、炎性因子、胞质酶等,在生物技术的推动下,新的特异性标志物被开发和验证。     

蜂胶提取物的安全性试验研究

目的 探讨蜂胶的乙醇提取物（EEP）的安全性。方法 用0.5％的EEP对家兔进行皮肤急性毒性试验、皮肤刺激试验以及对豚鼠的过敏试验。结果 EEP低剂量、高剂量皮肤破损组和对照组皮肤破损组各有一只家免,在24 h观察到皮肤破损处微红,48 h消失,其余各实验兔的皮肤、毛发、眼、粘膜、呼吸、中枢神经系统均无任何中毒表现;按照皮肤刺激反应强度,评价标准,完整皮肤组平均分为0,判为无刺激性;破损皮肤组平均分值为033＜0.50,亦判为无刺激性;A组空白对照组和B组EEP组动物均无红斑和水肿反应,判为无致敏性。结论 蜂胶提取物EEP在对实验动物体外寄生虫净化中安全、无毒、无刺激。     

不同运动图象同时刺激左右眼时的交替视动震颤(OKN)现象

采用了同时对左右眼分别以不同的运动图象刺激的实验方法,来测量及分析其OKN眼动反应,探索在OKN反映中两眼之间的输入关系以及眼动控制机制。实验结果发现在两眼的刺激图象不一致时,眼动反应为交替的OKN反应,即中枢神经系统根据各眼的刺激速度,交替地控制产生OKN眼动反应。本文还从闭环控制上讨论了视网膜上速度误差信号的作用。     

不同运动图象同时刺激左右眼时的交替视动震颤(OKN)现象

采用了同时对左右眼分别以不同的运动图象刺激的实验方法,来测量及分析其OKN眼动反应,探索在OKN反映中两眼之间的输入关系以及眼动控制机制。实验结果发现在两眼的刺激图象不一致时,眼动反应为交替的OKN反应,即中枢神经系统根据各眼的刺激速度,交替地控制产生OKN眼动反应。本文还从闭环控制上讨论了视网膜上速度误差信号的作用。     

一种体外皮肤腐蚀性试验替代方法的建立

目的建立皮肤腐蚀性的体外检测方法—大鼠经皮电阻试验(TER),优化OECD指南标准TG 430大鼠经皮电阻方法结果判定标准,并评价该方法作为替代方法用于评估化妆品原料的皮肤腐蚀性检测可行性。方法参照经合组织(OECD)化学品检测指南中TG 430体外皮肤腐蚀性大鼠经皮电阻试验的流程,使用Wistar大鼠对16种参考化学物质进行皮肤腐蚀性检测,设定不同的判定标准方案,通过对比筛选出最优的判定标准方案;并在5个实验室间进行11种参考物质的结果比对。结果改良后的TER结果判定方案结论与参考化学物质的实际腐蚀性结果具一致性(Kappa值0.64),改良方案B的特异性为66.7%,敏感性为100%,效能最高;实验室间比对结论差异无显著性(P0.05),实验室间对11种参考物质的判定一致率为72.7%。结论经改良的大鼠经皮电阻试验可较好的筛选化学物质的腐蚀性,有望在我国的替代毒理学及化学物质安全性评价中发挥重要的作用。     

胶原酶消化法分离制备罗非鱼和中华鳖的胰岛细胞及其生物活性

目的探讨罗非鱼、中华鳖胰岛细胞分离提取的方法及对比两者的生物学活性差异。方法采用胶原酶消化分离罗非鱼、中华鳖胰岛细胞,光镜下观察其形态结构。在体外用不同浓度的葡萄糖刺激胰岛细胞,测定其生物学活性。结果罗非鱼、中华鳖胰岛细胞在体外对不同浓度的葡萄糖刺激具有明确的生物学反应,并随着葡萄糖浓度的增加胰岛素的产生也相应增加。结论采用胶原酶消化分离罗非鱼、中华鳖胰岛细胞的方法可行,胰岛细胞在体外对不同浓度的葡萄糖刺激产生胰岛素并具有正相关,其为鱼纲、爬行纲与哺乳纲动物之间的胰岛细胞移植奠定了实验基础。     

体外皮肤检测模型的组织工程研究进展

皮肤刺激试验是临床前安全评价的常见项目,由于3R原则的发展,现逐渐采用体外皮肤检测模型来替代传统的动物实验。然而在国内皮肤模型的研究还处于起步阶段,种子细胞和支架材料是目前研究的主要内容。原代细胞和永生化细胞是皮肤刺激试验模型的种子细胞中较常用的两类。支架材料应用较广的是天然材料、合成材料和复合材料,而国外批量生产的模型中支架材料现阶段还是以天然材料为主。随着科技发展纳米技术也被利用来制备支架材料,使得皮肤模型的研究进入更深的领域。     

The development and evaluation of in vitro alternative assays: a personal perspective

Over the past 30 years, FRAME has actively participated in the development, evaluation and validation of in vitro alternative methods through the FRAME Alternatives Laboratory (FAL) in the University of Nottingham Medical School. Much has been learned through collaboration with industry (especially the cosmetics industry), other organisations (especially ECVAM), and certain individuals (notably Dr Bj?rn Ekwall), particularly in relation to the need to use human cell cultures and to obtain, wherever possible, high-quality human data for use in in vivo/in vitro comparisons. Reference is made to the author's experience as Director of the FAL, notably in the development of in vitro assays for basal cytotoxicity, phototoxicity and the effects of repeated dosage.     

Assessment of the eye irritating properties of chemicals by applying alternatives to the Draize rabbit eye test: the use of QSARs and in vitro tests for the classification of eye irritation

Huggins has reported on the current situation relating to the development of alternatives to the Draize eye irritation test with rabbits, and an ECVAM Working Group have reviewed the efforts needed in order to replace this animal test within the next 10 years by using the results of non-animal assessment methods. Our report reviews regulatory experience gained over the last 20 years with the EU chemicals notification procedure with respect to the assessment of eye lesions observed in Draize tests. The nature of eye lesions and their importance for classification and labelling of possible hazards to human eyes are evaluated and discussed, with a view to promoting the development of specific in vitro assays which are able to discriminate between eye damage, moderate eye irritation, and minor irritation effects which are completely reversible within a few days. Structural alerts for the prediction of eye irritation/corrosion hazards to be classified and labelled according to international classification criteria, are presented, which should be validated in accordance with internationally agreed (OECD) principles for (Q)SAR system validation. Physicochemical limit values for prediction of the absence of any eye irritation potential relevant for human health can make available a definition of the applicability domains of alternative methods developed for the replacement of the Draize eye irritation test.     

Growing old disgracefully: the cosmetic use of botulinum toxin

The explosive growth in the use of botulinum toxin for cosmetic purposes has undoubtedly had an impact on the number of animals used in the potency testing of this product. The test used is a classical LD50, a severe procedure during which animals experience increasing paralysis until the occurrence of death. The enthusiastic adoption by the general public of the use of botulinum toxin as an anti-wrinkle treatment has, at least in Europe, paradoxically taken place against a background of moves to stop animal testing of cosmetics and cosmetic ingredients. There appears to be a dearth of information aimed at the public concerning botulinum toxin testing. Botulinum toxin does have important medical applications; however, the question arises whether a blanket licence for the testing can be justified, when a large proportion of the product is being used cosmetically. A further question is why death continues to be the endpoint of the potency test, when a more-humane endpoint has been proposed. In addition, a number of alternative methods have been developed, which could have the potential to replace the lethal potency test altogether. These methods are discussed in this paper, and the importance of establishing a strategy for their validation is emphasised, a need that has become even more urgent in the light of the recently published draft monograph on botulinum toxin by the European Pharmacopoeia Commission.     

Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: State of the science and planning the way forward

Potency testing of most human and veterinary rabies vaccines requires vaccination of mice followed by a challenge test using an intracerebral injection of live rabies virus. NICEATM, ICCVAM, and their international partners organized a workshop to review the availability and validation status of alternative methods that might reduce, refine, or replace the use of animals for rabies vaccine potency testing, and to identify research and development efforts to further advance alternative methods. Workshop participants agreed that general anesthesia should be used for intracerebral virus injections and that humane endpoints should be used routinely as the basis for euthanizing animals when conducting the mouse rabies challenge test. Workshop participants recommended as a near-term priority replacement of the mouse challenge with a test validated to ensure potency, such as the mouse antibody serum neutralization test for adjuvanted veterinary rabies vaccines for which an international collaborative study was recently completed. The workshop recommended that an in vitro antigen quantification test should be a high priority for product-specific validation of human and non-adjuvanted veterinary rabies vaccines. Finally, workshop participants recommended greater international cooperation to expedite development, validation, regulatory acceptance, and implementation of alternative test methods for rabies vaccine potency testing.     

The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): a review of the ICCVAM test method evaluation process and current international collaborations with the European Centre for the Validation of Alternative Methods (ECVAM)

Over the last decade, national authorities in the USA and Europe have launched initiatives to validate new and improved toxicological test methods. In the USA, the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and its supporting National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) were established by the Federal Government to work with test developers and Federal agencies to facilitate the validation, review, and adoption of new scientifically sound test methods, including alternatives that can refine, reduce, and replace animal use. In Europe, the European Centre for the Validation of Alternative Methods (ECVAM) was established to conduct validation studies on alternative test methods. Despite differences in organisational structure and processes, both organisations seek to achieve the adoption and use of alternative test methods. Accordingly, both have adopted similar validation and regulatory acceptance criteria. Collaborations and processes have also evolved to facilitate the international adoption of new test methods recommended by ECVAM and ICCVAM. These collaborations involve the sharing of expertise and data for test-method workshops and independent scientific peer reviews, and the adoption of processes to expedite the consideration of test methods already reviewed by the other organisation. More recently, NICEATM and ECVAM initiated a joint international validation study on in vitro methods for assessing acute systemic toxicity. These collaborations are expected to contribute to accelerated international adoption of harmonised new test methods that will support improved public health and provide for reduced and more-humane use of laboratory animals.     

Bioprocessing of differentiated plant in vitro systems

Plant cells contain a wide range of interesting secondary metabolites, which are used as natural pigments and flavoring agents in foods and cosmetics as well as phyto‐pharmaceutical products. However, conventional industrial extraction from whole plants or parts of them is limited due to environmental and geographical issues. The production of secondary metabolites from in vitro cultures can be considered as alternative to classical technologies and allows a year‐round cultivation in the bioreactor under optimal conditions with constant high‐level quality and quantity. Compared to plant cell suspensions, differentiated plant in vitro systems offer the advantage that they are genetically stable. Moreover, the separation of the biomass from culture medium after fermentation is much easier. Nevertheless, several investigations in the literature described that differentiated plant in vitro systems are instable concerning the yield of the target metabolites, especially in submerged cultivations. Other major problems are associated with the challenges of cultivation conditions and bioreactor design as well as upscaling of the process. This article reviews bioreactor designs for cultivation of differentiated plant in vitro systems, secondary metabolite production in different bioreactor systems as well as aspects of process control, management, and modeling and gives perspectives for future cultivation methods.     

Report on the international workshop on alternative methods for Leptospira vaccine potency testing: State of the science and the way forward

Routine potency testing of Leptospira vaccines is mostly conducted using a vaccination–challenge test that involves large numbers of hamsters and unrelieved pain and distress. NICEATM, ICCVAM, and their international partners organized a workshop to review the state of the science of alternative methods that might replace, reduce, and refine the use of animals for veterinary Leptospira vaccine potency testing and to identify ways to advance improved alternative methods. Vaccine manufacturers were encouraged to initiate or continue product-specific validation using in vitro enzyme-linked immunosorbent assays as replacements for potency testing of four common Leptospira serogroups. Participants discussed the potential for eliminating the back-titration procedure in the hamster challenge assay, which could reduce animal use by 50% for each individual potency test. Further animal reduction may also be possible by using cryopreserved Leptospira stock to replace continual passaging through hamsters. Serology assays were identified as a way to further reduce and refine animal use but should be considered only after attempting in vitro assays. Workshop participants encouraged consideration of analgesics and use of earlier humane endpoints when the hamster vaccination–challenge potency assay is used. International harmonization of alternative potency methods was recommended to avoid duplicative potency testing to meet regionally different requirements.